Use of Evidence in Decision Models

Evidence-Based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice, Second Edition

Volumn , Issue , 2010, Pages 106-113

  Coyle, Doug ^a   Lee, Karen M ^b   Cooper, Nicola J ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Canadian Agency for Drugs and Technologies in Health   (Canada)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Analysis of impact of different sources of data; Decision models using evidence; Different sources of data previous guidance; Osteoporosis highlights potential concern over adoption of data; Parameter estimates of review of existing decision models; Published decision models a review

Indexed keywords

EID: 84881669451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444320398.ch9     Document Type: Chapter

References (34)

1. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics 1997; 6(3): 217-227.
2. Jefferson T, Mugford M, Gray A, Demicheli V. An exercise on the feasibility of carrying out secondary economic analyses. Health Economics 1996; 5(2): 155-165.
3. Freemantle N. Maynard A. Something rotten in the state of clinical and economic evaluations? Health Economics 1994; 3(2): 63-67.
4. Kassirer JP, Angell J. The Journal's policy on costeffectiveness analyses. New England Journal of Medicine 1994; 331(10): 669-670.
5. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 1991; 324(19): 1362-1365.
6. Cranney A, Coyle D, Welch V, Lee KM, Tugwell P. A review of economic evaluations in osteoporosis. Arthritis Care Research 1999; 12(6): 425-434.
7. Coyle D, Lee KM. Improving the evidence base of economic evaluations. In: Donaldson C, Mugford M, Vale L (eds) Evidence-Based Health Economics. London: BMJ Books, 2002.
8. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. Journal of Health Services Research and Policy 2005; 10(4): 245-250.
9. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Canadian Medical Association Journal 1979; 121(9): 1193-1254.
10. Mogyorosy Z, Smith PC. The Main Methodological Issues in Costing Health care Services: a literature review (Centre for Health Economics Research Paper No.7). York: Centre for Health Economics, University of York, 2005.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
12. Coyle D, Maunsell E, Wells GA, et al. Differences in prefe rence values between cultural groups: women's preferences over lifetime risks associated with postmenopausal osteo porosis therapy. Annual Meeting of the International Society of Technology Assessment in Health care 1999; 15: 81.
13. Coyle D, Cranney A, Lee KM, Welch V, Tugwell P. Costeffectiveness of nasal calcitonin in postmenopausal women. Use of Cochrane Collaboration methods for meta analysis in economic evaluation. Pharmacoeconomics 2001; 19(5): 565-575.
14. Cranney A, Coyle D, Pham B, et al. The psychometric properties of patient preferences in osteoporosis. Journal of Rheumatology 2001; 28(1): 132-137.
15. Liberman UA, Weiss SR, Broll J, et al., for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New England Journal of Medicine 1995; 333(22): 1437-1443.
16. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535-1541.
17. Cummings SR, Black DM, Thompson DE, et al., for the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures-results from the Fracture Intervention Trial. Journal of the American Medical Association 1998; 280(24): 2077-2082.
18. Kannus P, Parkkari J, Sievanen H, Heinonen A, Vuori I, Jarvinen M. Epidemiology of hip fractures. Bone 1996; 18(1): 57S-63S.
19. Karagas MR, Lu-Yao GL, Barrett JA, Beach ML, Baron JA. Heterogeneity of hip fracture: age, race, sex, and geographic patterns of femoral neck and trochanteric fractures among the US elderly. American Journal of Epidemiology 1996; 143(7): 677-682.
20. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. Journal of Epidemiology and Community Health 1990; 44(3): 241-245.
21. Best L, Milne R. Bisphosphonates (Alendronate and Etidronate) in the Management of Osteoporosis (Development and Evaluation Committee Report No.79). Southampton: Wessex Institute for Health Research and Development, 1998.
22. Silverman SL, Simons R. Utility values for osteoporosis outcomes (Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, Abstract W443). Bone 1998; 23(5): S398.
23. Goeree R, O'Brien B, Pettitt D, Cuddy L, Ferraz M, Adachi J. An assessment of the burden of illness due to osteoporosis in Canada. Journal of the Society of Obstetricians and Gynaecologists of Canada 1996; 18(suppl); 15-22.
24. Kristiansen IS, Falch JA, Andersen L, Aursnes I. Bruk av alendronat ved osteoporose-er det kostnadseffektivt? Tidsskrift for Den Norske Laegeforening 1997; 117(18): 2619-2622.
25. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Medical Journal of Australia 1992; 156(5): 312-216.
26. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis International 1996; 6(4): 265-275.
27. Tosteson ANA, Weinstein MC. Cost-effectiveness of hormone replacement therapy after the menopause. Baillière's Clinical Obstetrics and Gynaecology 1991; 5(4): 943-959.
28. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making 1985; 5(2): 157-177.
29. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17(5): 479-500.
30. Coyle D, Buxton MJ, O'Brien BJ. Measures of importance for economic analysis based on decision modeling. Journal of Clinical Epidemiology 2003; 56(10): 989-997.
31. Greenland S. Multiple-bias modelling for analysis of observational data. Journal of the Royal Statistical Society: Series A 2005; 168(2): 267-306.
32. Prevost TC, Abrams KR, Jones DR. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer screening. Statistics in Medicine 2000; 19(24): 3359-3376.
33. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex costeffectiveness modelling. Statistics in Medicine 2003; 22(23): 3687-3709.
34. Trichtler D. Modelling study quality in meta-analysis. Statistics in Medicine 1999; 18(16): 2135-2145.